Response to Ong et al., 'Hair-Raising Costs: Evaluating Botulinum Toxin Treatment for Androgenetic Alopecia'

The study discussed in the document evaluates the efficacy of botulinum toxin (BT) for treating male androgenetic alopecia (AGA) through a triple-blind, randomized clinical trial. Despite the potential of new treatment options, the study concludes that BT does not play a role in managing male AGA. The trial used a high dose of BT (50 IU/cm²) and precise methodologies, such as hair-to-hair trichoscopy, to ensure accurate results. The authors emphasize the importance of considering efficacy, safety, and cost-effectiveness in treatment decisions, highlighting that their findings may help prevent unnecessary societal costs from ineffective therapies.